Saturday, August 29, 2020

Asian countries & the race for COVID-19 Vaccine

This article is by

Share this article

Article Contributor(s)

Charvi Trivedi

Article Title

Asian countries & the race for COVID-19 Vaccine

Publisher

Global Views 360

Publication Date

August 29, 2020

URL

Representative image of Vaccine

Representative image of Vaccine | Source: Dimitri Houtteman via Unsplash

Our relationship with the new strain of coronavirus is almost 8 months strong now. Countries like the US, Russia, UK, China, India, and many more have already set their brainy scientists in the task of developing a vaccine, turning it into a race which desperately needs a winner, since no one wants this deadly relationship to endure. Several attempts have proved to be successful, especially in countries like Russia, USA, India, and China.

China was the first to start scouring for a vaccine the day WHO declared that the new strain of SARS-CoV, originating in Wuhan-China, has resulted in a pandemic. It is a fierce competitor, especially to the US, as almost 8 of the 24 promising vaccines approved for clinical trials are from China. It used the technology of ‘inactivated vaccine’ which basically means killing the actual virus and using that to create a vaccine. This method is quite useful in treating measles and influenza, thus, increasing the chances of success in the case of COVID-19 as well.

“It’s a tried and true strategy”, Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia, said  about the inactivated vaccine. One potential vaccine from China-based Sinopharm is already in the phase 3 of trials whereas Sinovac will enter the third phase this month. Moreover, China has permitted Sinovac and Sinopharm to dilute phase 1 and 2 of vaccine trials on humans to hasten the process.

The head of the Chinese Center for Disease Control and Prevention, Gao Fu, had also been injected with a potential vaccine on July 28, 2020. “I’m going to reveal something undercover: I am injected with one of the vaccines'' Gao Fu said in a webinar hosted by Alibaba Health, an arm of the Chinese e-commerce giant, and Cell Press, an American publisher of scientific journals. However, he did not reveal any more details about how and when exactly he administered himself with the vaccine and ‘hopes’ that the vaccine works.

Vladimir Putin, President of Russia | Source: Wikimedia

Elsewhere in Russia, on August 11, 2020, President Vladimir Putin proudly announced that Russia was the first country to grant regulatory approval to their vaccine after carrying out human trials for less than 2 months by the Gamalei Institute in Moscow. Regulatory approval permits vaccination of the masses. Although it has not undergone phase 3 of trials, Russia expects to initiate mass production of the vaccine by the end of this year. Kirill Dmitriev, head of Russia's sovereign wealth fund states that the vaccine will be called ‘Sputnik V’, named after Sputnik 1, the first satellite launched by Soveit Union which was a euphoric moment for Russia. More recently, China and Russia have joined hands in proceeding with the clinical trials of their vaccines.

These two instances seem to bring a new hope for the future, yet raise alarms and invite scepticism from the experts in the field of public health. One major concern is that without prolonged trials, vaccines should not be authorized for public use. Anthony Fauci, an infectious disease expert based in the US said “I do hope the Chinese and the Russians are actually testing the vaccines before they are administering the vaccine to anyone. Because claims of having a vaccine ready to distribute before you do testing is problematic at the very least”. Hence, some people are still in doubt regarding the safety of the product. Putin, however, rubbished such concerns and said "I know that it works quite effectively, forms strong immunity, and I repeat, it has passed all the needed checks".

An Indian biotechnological company, Bharat Biotech developed ‘Covaxin’ in collaboration with Indian Council for Medical Research (ICMR), using the mechanism of inactivated vaccine. It was successful in getting approval for human trials which were scheduled to begin in July, 2020. Initial reports stated that it would be ready for mass use by August 15, 2020, which also marked the 73rd Independence Day of India. However, Bharat biotech was clear in letting the public know that phase 1 of the trials are still on-going. ICMR cleared the confusion by stating that it would prepare the results of the phase 1 trials by August 15, 2020, not the actual vaccine for use. Phase 2 of the trials are awaited in September, 2020.

So far, the results of phase 1 trials have been positive as no serious side-effects are observed in the vaccine candidates. “The vaccine has been safe. No adverse effect has been reported. Even the point of injection pain, which is normal in vaccines, has been very mild” said Dr Kushwaha of Prakhar Hospital.

Meanwhile, the South Korean government stated on August 21, 2020, that it will secure adequate vaccine supply to its citizens by cooperating with international bodies and promoting local drug development. Three South Korean companies have started the process of making a vaccine and all are in the clinical trial phase. Bill Gates asserts that the South Korean pharmaceutical company, SK Bioscience, will have around 200 million vaccine doses ready by June 2021.

Japan is jointly collaborating with the UK, France and other European countries to establish a $20 billion fund to buy coronavirus vaccines, with Japan pledging a contribution of $800 million. It’s vaccine program aims to focus on giving primary attention to its medical workers and the elderly people of the country when the first doses of the vaccine are made. The state-funded vaccination program is believed to be officially adopted by Japan in September this year with negotiations with the UK and US based drug makers already in place.

With the race to bring COVID-19 vaccine seemingly coming to a close and it will hopefully be ready by the end of 2020 or early 2021. Till then, the entire world is watching this race with bated breath.

Support us to bring the world closer

To keep our content accessible we don't charge anything from our readers and rely on donations to continue working. Your support is critical in keeping Global Views 360 independent and helps us to present a well-rounded world view on different international issues for you. Every contribution, however big or small, is valuable for us to keep on delivering in future as well.

Support Us

Share this article

Read More

February 4, 2021 5:18 PM

Interviewing Dr. Kamil Zwolski: Professor of International Politics turned Edupreneur

Today we talk with Kamil Zwolski, PhD, who is Associate Professor in International Politics in the UK and who recently launched MyGlobalPolitics.com.

Q: Kamil, what is the idea of MyGlobalPolitics?

Kamil: The idea is to explore how the Internet can open up new opportunities for learning International Relations and related topics, such as international security, geopolitics or the role of China. On the one hand, there are people who are interested in what’s going on in the world and would like to explore that topic in more depth. But on the other hand, they are not planning to study it at a university. There are also people who do study International Relations at a university and want some extra resources to do better and get better grades. The website also offers help to those who need help with their job applications, university applications, PhD proposals, policy papers and other projects on International Relations.    

Q: Is there a market for educational products in an academic niche?

Kamil: That’s what I am finding out. It is true that most people who want to sell educational products, such as online courses, go for one of the three big niches: making money, getting fit or dating/relationships. But I am an academic and an expert on International Relations. And that’s what I want to do. I also like the world of online education and entrepreneurship. In that sense, I am what is sometimes called an edupreneur.

Q: What do you do for your full time job?

Kamil: I am Associate Professor in International Relations at one of the leading UK universities. I am a published author with hundreds of citations on Google scholar, including two peer-reviewed books. I am also a passionate educator and a Senior Fellow of the UK’s Higher Education Academy. All it means I am serious about improving my teaching skills and making sure students learn stuff when they work with me.

Q: What are your hopes and plans for MyGlobalPolitics?

Kamil: I see the future of education as developing alongside two parallel routes. One route will be the familiar system of higher education institutions. Contrary to what some predict, I don’t think universities will go away in any foreseeable future. Over centuries, they have accumulated enough legitimacy to be seen as undisputed pillars of how people go about getting more advanced knowledge. Granted, universities - like all institutions - have to adapt and some will do that better than others. But as a category of institutions, they will continue to exist.

Then there is this other route, which we already see, but which is nowhere near its full potential. And that’s online education. We see some well-established players in that field, such as Udemy, but there is much scope for greater diversity within that category of services. The big players will stay there and may get even bigger, as more people choose online as a way to learn new stuff. But in addition to those large players, individual edupreneurs will be building their own little communities within their areas of specialism. And that’s where I see MyGlobalPolitics - a community of learners interested in International Relations, who want to get in-depth knowledge on the subject or who have some projects they want to work on. That’s my ambition for this platform.

Read More